High Growth Tech Stocks to Watch in January 2025

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these optimistic projections can be crucial for investors looking to capitalize on emerging opportunities in this dynamic sector.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Exelixis	62.05%	20.47%	★★★★★★
Super Micro Computer	24.13%	24.28%	★★★★★★
Ardelyx	21.46%	55.24%	★★★★★★
AVITA Medical	33.33%	51.81%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
TG Therapeutics	29.87%	43.91%	★★★★★★
Bitdeer Technologies Group	50.44%	122.48%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.43%	56.40%	★★★★★★
Travere Therapeutics	30.02%	61.89%	★★★★★★

Click here to see the full list of 229 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Soleno Therapeutics (NasdaqCM:SLNO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for rare diseases, with a market cap of $2.02 billion.

Operations: Soleno Therapeutics focuses on developing and commercializing treatments for rare diseases. As a clinical-stage biopharmaceutical company, its operations are centered around advancing novel therapeutics through the development pipeline.

Soleno Therapeutics has strategically positioned itself within the high-growth tech sphere through its innovative approach to treating Prader-Willi syndrome, a rare genetic disorder. With a recent $50 million tranche from a $200 million loan agreement aimed at advancing their flagship product, DCCR, the company underscores its commitment to significant R&D endeavors. This financial maneuver is complemented by an anticipated revenue growth of 51.8% per year, outpacing the broader U.S. market's growth rate of 9%. Furthermore, Soleno's participation in key healthcare conferences and extended FDA review periods for DCCR highlight both the challenges and potential within biotech's competitive landscape. The company’s focus on specialized drug development for underserved medical needs could reshape treatment standards and drive future profitability, projected to materialize within three years.

• Click to explore a detailed breakdown of our findings in Soleno Therapeutics' health report.

• Examine Soleno Therapeutics' past performance report to understand how it has performed in the past.

Krystal Biotech (NasdaqGS:KRYS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing genetic medicines for rare diseases in the United States, with a market cap of approximately $4.27 billion.

Operations: Krystal Biotech generates revenue primarily through its business of developing and commercializing pharmaceuticals, amounting to $241.52 million. The company is focused on providing genetic medicines for rare diseases within the U.S.

Krystal Biotech's recent surge in profitability, marked by a transition to profit this year and an impressive annual earnings growth forecast of 36.6%, underscores its dynamic position in the biotech sector. The company's significant investment in research and development, which is evident from its R&D expenses constituting a substantial portion of revenue, aligns with its strategy to innovate continuously. Notably, Krystal's revenue growth projection stands at 28.4% annually, outstripping the broader U.S market average of 9%. This robust financial performance is complemented by promising clinical outcomes from their KYANITE-1 study for lung cancer treatment, showcasing early monotherapy activity particularly in advanced non-small cell lung cancer cases with an objective response rate of 27% and disease control rate of 73%.

• Get an in-depth perspective on Krystal Biotech's performance by reading our health report here.

• Review our historical performance report to gain insights into Krystal Biotech's's past performance.

Legend Biotech (NasdaqGS:LEGN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cell therapies for oncology and other indications, with operations in the United States, China, and internationally, and a market cap of approximately $5.99 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $520.18 million. Legend Biotech focuses on the discovery, development, and commercialization of innovative cell therapies across multiple regions including the United States and China.

Legend Biotech's recent executive shifts, including the appointment of Jessie Yeung as interim CFO, underscore a strategic realignment amid its ambitious growth trajectory. With a robust annual revenue growth rate of 30.6% and an anticipated earnings surge of 56.4%, Legend is poised to capitalize on advancements in multiple myeloma treatments, evidenced by the promising Phase 3 CARTITUDE-4 study results showing significant MRD-negativity rates. This positions CARVYKTI® as a pivotal therapy in earlier treatment lines, potentially reshaping patient outcomes and bolstering Legend's market stance despite current unprofitability.

• Unlock comprehensive insights into our analysis of Legend Biotech stock in this health report.

• Assess Legend Biotech's past performance with our detailed historical performance reports.

Turning Ideas Into Actions

• Delve into our full catalog of 229 US High Growth Tech and AI Stocks here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com